Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial

Plus news about Sino Biopharm and AtomVie. Yarrow gets more money: New Haven-based Yarrow Bioscience priced a $150 million offering at $26 per share {$YARW}, about $2.50 below its Thursday closing ...